InvestSMART

SomnoMed Limited (ASX:SOM)

ALERT: Price-sensitive ASX Announcement for SOM
Current share price for SOM : $0.535 -0.125 (-18.94%)+
Announcement
Release
27 Feb 2026 8:12AM
Price at Release
$0.660
Full Release
download
Summary
SomnoMed Limited reported a net profit after tax of $792,000 for the half-year ended 31 December 2025, marking a significant turnaround from a loss of $106,000 in the previous corresponding period. Revenue increased by 13.1% to $60,717,000, with notable contributions from North America and Europe. The company did not declare any dividends for the period. SomnoMed focused on producing and selling devices for sleep-related disorders and maintained a strong financial position with total assets of $79,899,000 and total equity of $50,036,000. The report indicated no significant changes in the state of affairs or events after the reporting date that could affect the company's operations.
Key Points
  • Net profit after tax of $792,000, up from a loss of $106,000.
  • Revenue increased by 13.1% to $60,717,000.
  • No dividends declared for the half-year.
  • Total assets reported at $79,899,000 and total equity at $50,036,000.
  • Focus on producing and selling devices for sleep-related disorders.
  • No significant changes in state of affairs or post-reporting events affecting operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.